Specifically, the total eGFR slope was 1.16 ml/min/1.73m2/year slower, the risk of major cardiovascular events was decreased by 18%, and the risk of all-cause mortality was reduced by 20%
Link to existing habits : Pair your injection with an established weekly routine, such as a specific meal, religious service attendance, or weekend activity
Ozempic is paving the way for other GLP-1 drugs to treat conditions beyond kidney disease The FLOW trial results, along with the recent announcement that Wegovy is approved to reduce cardiovascular risk in people with obesity, are the latest indications that these drugs have benefits for conditions beyond their original intended treatment of type 2 diabetes
Every item below is independently verifiable - don't take anyone's word for any of them, including this article
One study found that a 5% to 10% reduction in body weight significantly reduced stress urinary incontinence episodes in obese women
Still, if there are any concerns about kidney health while taking semaglutide, a healthcare provider can monitor kidney function with routine tests
